Focused on therapies for rare and serious diseases, the company develops small‑molecule drugs targeting cellular metabolism and inflammation pathways. Its pipeline has centered on treatments for neurological and kidney disorders, including an FDA‑approved therapy for Friedreich’s ataxia and investig...
1 member of Congress has disclosed 2 trades in Reata Pharmaceuticals, Inc. (RETA), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 1 sale. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2021-01-04 | Christopher L. Jacobs | sell | $1K – $15K |
| 2020-12-28 | Christopher L. Jacobs | buy | $1K – $15K |